Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to 206.45%.

  • Voyager Therapeutics' EBITDA Margin fell 1717100.0% to 206.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 403.92%, marking a year-over-year decrease of 4198500.0%. This contributed to the annual value of 81.7% for FY2024, which is 1347000.0% down from last year.
  • As of Q3 2025, Voyager Therapeutics' EBITDA Margin stood at 206.45%, which was down 1717100.0% from 642.38% recorded in Q2 2025.
  • Voyager Therapeutics' EBITDA Margin's 5-year high stood at 1516.65% during Q4 2022, with a 5-year trough of 3252.89% in Q1 2022.
  • In the last 5 years, Voyager Therapeutics' EBITDA Margin had a median value of 332.84% in 2021 and averaged 605.36%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first tumbled by -29200500bps in 2022, then skyrocketed by 33353800bps in 2023.
  • Quarter analysis of 5 years shows Voyager Therapeutics' EBITDA Margin stood at 20.3% in 2021, then skyrocketed by 7371bps to 1516.65% in 2022, then crashed by -96bps to 62.84% in 2023, then plummeted by -984bps to 555.29% in 2024, then surged by 63bps to 206.45% in 2025.
  • Its last three reported values are 206.45% in Q3 2025, 642.38% for Q2 2025, and 474.05% during Q1 2025.